Rivastigmine Bioequivalence Trial With Multiple Applications of Transdermal Patches (9.5 mg/24 h)
Status:
Active, not recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The present clinical trial will be conducted in order to compare the bioavailability of
rivastigmine and to assess bioequivalence at steady-state of the marketed Test product
Rivastigmine twice-weekly 9,5 mg/24 h transdermal patch (Manufacturer: Luye Pharma AG,
Germany) and the marketed Reference product Exelon® 9.5 mg/24 h transdermal patch
(Manufacturer: LTS Lohmann Therapie-Systeme AG, Germany) after multiple patch applications.
Each of both treatments will last for 11 days with a washout period of at least 14
treatment-free days between the treatments.